DiZhe Pharmaceutical (688192.SH): Two core products for blood tumors selected for the 2026 European Hematology Association (EHA) Annual Meeting.
Dezhe Pharmaceuticals (688192.SH) announced that two core products in the company's blood cancer pipeline, Goralzol (generic name: Glixiatini capsules) and Bireltinib, have a total of 9 latest research results selected for the 2026 European Hematology Association (EHA) Annual Meeting. The conference will be held in Stockholm, Sweden from June 11th to 14th. The selected studies cover multiple treatment strategies and subtypes exploration in the field of peripheral T-cell lymphoma (PTCL) and B-cell lymphoma, further demonstrating the company's global innovative layout in the field of blood cancer.
Di Zhe Pharmaceuticals (688192.SH) announced that two core products in the company's blood cancer pipeline - Gao Ruizhe (generic name: golixetinib capsules) and Birelentinib, have a total of 9 new research achievements selected for the 2026 European Hematology Association (EHA) Annual Meeting. The conference will be held in Stockholm, Sweden from June 11 to 14. The selected research covers multiple treatment strategies and subtypes exploration in the treatment of Peripheral T-cell lymphoma (PTCL) and B-cell lymphoma, further demonstrating the company's global innovative layout in the field of blood cancer.
Related Articles
China Communications Construction Company (01800) spent 1017.95 million yuan to repurchase 1.4796 million A-shares on May 13th.
Semiconductor service provider Suchness Tech (SUCH.US) applies for listing in the United States and plans to raise $20 million.
CICC(03908): The coupon rate for the next 2 years of "23 Zhongjin G3" will be lowered by 157 basis points to 1.30%.
China Communications Construction Company (01800) spent 1017.95 million yuan to repurchase 1.4796 million A-shares on May 13th.
Semiconductor service provider Suchness Tech (SUCH.US) applies for listing in the United States and plans to raise $20 million.
CICC(03908): The coupon rate for the next 2 years of "23 Zhongjin G3" will be lowered by 157 basis points to 1.30%.
RECOMMEND
Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026
HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026
The Chip Stock Frenzy Is Still Accelerating
11/05/2026
